Asiaticoside（AS）, a pivotal active ingredient derived from the traditional Chinese herb Centella asiatica, has emerged as a revolutionary “structural disassembly agent” that selectively degrades STAT3 protein, unlocking novel prospects for the treatment of chronic kidney disease（CKD）.
In March 2026, nephrologists from Zhongda Hospital Affiliated to Southeast University published a landmark study in Phytomedicine（Volume 155, June 2026, Article 158049）titled Asiaticoside attenuates renal fibrosis by targeting STAT3 to restore Th17/Treg homeostasis. This research uncovered the precise mechanism by which asiaticoside combats renal fibrosis, a progressive pathological process that drives over 10% of the global population toward end-stage renal disease.
The Dilemma of Renal Fibrosis
Renal fibrosis, the core pathological driver of CKD progression, was once misunderstood as simple scarring. Modern studies reveal it stems from immune system imbalance: overactivated Th17 cells release excessive IL-17A triggering chronic inflammation, while insufficient Treg cells fail to suppress inflammatory responses. This Th17/Treg imbalance accelerates renal tissue scarring and functional decline, with no targeted clinical drugs available to correct this disorder.
Asiaticoside Directly Targets and Destabilizes STAT3
Surface Plasmon Resonance（SPR）assays confirmed that asiaticoside binds strongly to STAT3 protein, with a dissociation constant（KD）of 4.736×10⁻⁶ M for mouse STAT3 and 1.586×10⁻⁵ M for human STAT3, indicating high-affinity interactions across species.
Unlike traditional STAT3 inhibitors that block protein activity, asiaticoside acts as a “structural disassembly agent” by inserting into the SH2 domain (hinge region) of STAT3. This binding destabilizes the protein structure, prompting natural clearance of dysfunctional STAT3 by cellular degradation systems.
Mechanistic Validation: Lock-Instability Degradation Pathway
Combining network pharmacology, transcriptomic analysis and molecular docking, researchers identified STAT3 as the primary target of asiaticoside. Further experimental verification solidified the mechanism:
- DARTS + LC-MS/MS detection captured the direct binding of asiaticoside to the SH2 domain of STAT3, protecting the protein from enzymatic cleavage.
- Pharmacological intervention assays showed that STAT3 inhibitor Stattic replicated the anti-fibrotic effects of asiaticoside, while STAT3 agonist Colivelin exacerbated renal fibrosis — an effect partially reversed by asiaticoside.
Precise Immune Regulation Without Side Effects
A distinguishing advantage of asiaticoside is its targeted immunomodulation:
- Reduced Th17 cell ratio and IL-17A expression
- Elevated Treg cell proportion and IL-10 secretion
- Restored Th17/Treg balance from 10.04% to 3.66%
- No alteration in total CD4+ T cell counts, avoiding non-specific immune suppression
Immunofluorescence staining further demonstrated that asiaticoside decreases both total STAT3 and phosphorylated p-STAT3 levels in renal tissues, achieving dual inhibition of protein activation and expression.
Developmental Potential and Future Perspectives
The STAT3-targeting mechanism of asiaticoside is evolutionarily conserved between humans and mice, supporting its translational potential. Its non-classical protein degradation pathway（independent of proteasomes, likely involving lysosomes or autophagy）offers a new strategy to overcome drug resistance in conventional targeted therapies.
Limitations requiring further investigation include:
- Validation in chronic nephropathy models beyond the UUO acute injury model
- Pharmacokinetic profiling of absorption, distribution, metabolism and excretion
- Elucidation of the exact intracellular degradation pathway
Proxima opinion
Asiaticoside represents a paradigm shift in anti-fibrotic therapy, acting as a natural “structural disassembly agent” to selectively degrade STAT3 and restore immune homeostasis. This discovery bridges traditional Chinese medicine and modern pharmacology, providing a safe, targeted candidate for chronic kidney disease intervention and inspiring a new generation of protein-targeted drug development.
References
2. Lee J, Jung E, Kim Y, Park J, Park J, Hong S, et al. Asiaticoside induces human collagen I synthesis through TGF-β receptor I kinase (TβRI kinase)-independent Smad signaling. Planta Medica. 2006;72(4):324-328. doi:10.1055/s-2005-916227.
3. Jiang H, Zhou X, Chen L. Asiaticoside delays senescence and attenuate generation of ROS in UV-exposure cells through regulates TGF-β1/Smad pathway. Experimental and Therapeutic Medicine. 2022;24(5):667. doi:10.3892/etm.2022.11603.
4. Kapoor S, Saraf S. Topical formulation of a new plant extract complex with refirming properties. Clinical and non-invasive evaluation in a double-blind trial. International Journal of Cosmetic Science. 2000;22(3):201-206. doi:10.1046/j.1467-2494.2000.00045.x.
5. Bae YS, Cho JW, Park JS, Jeong MH, Yeo KY, Lee KS. Asiaticoside increases aquaporin-3 protein expression in the cytoplasm of normal human epidermal keratinocytes. The Journal of Dermatology. 2012;39(11):901-907. doi:10.1111/j.1346-8138.2012.01633.x.
6. Wang C, Lan J, Feng C, Wang S, Zhao X, Liu W, et al. Mechanisms of asiaticoside in keloid treatment: Insights from a single-cell transcriptomic approach combined with network pharmacological analysis. Cell Death Discovery. 2023;9(1):136. doi:10.1038/s41420-023-01431-7.
7. Kim HY, Kwon J, Kim S, Park K, Kim J, Kim J. Enhanced skin-protective effects of a novel Centella asiatica variety (BT-Care) cultivated for 75 days via modulation of antioxidant defense, collagen synthesis, and skin barrier function. Nutrients. 2023;15(15):3348. doi:10.3390/nu15153348.
